RBP4 and infection: Systemic andgut inflammation is metabolically expensive and can result in adverse growth outcomes.17 Plasma RBP4, which is regarded as a negative acute phase reactant, is alsofrequently found to be reduced in settings of inflammation or infection.12 Hence, the aim of the current analysis also includes measuring theassociation of plasma RBP4 with the markers of systemic and gut inflammation.